Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Metals ions and neurodegeneration

Molina-Holgado, Francisco, Hider, Robert C., Gaeta, Alessandra, Williams, Robert, Francis, Paul·2007·BioMetals

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10534-006-9033-z

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 98

  1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain of Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329 · DOI · Paper page
  2. Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Phil Trans R Soc Lond B Biol Sci 358:1669–1677 · DOI · Paper page
  3. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629–640 · DOI · Paper page
  4. Antzutkin ON, Leapman RD, Balbach JJ, Tycko R (2002) Sopramolecular structural constraints on Alzheimer’s β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 41:15436–15450 · DOI · Paper page
  5. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 43:1–16 · DOI · Paper page
  6. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteosome system by protein aggregation. Science 292:1552–1555 · DOI · Paper page
  7. Bonilla E (2000) Huntington disease. A review. J Clin Invest 41:117–141
  8. Brion S, Mirol J, Psimaras A (1973) Recent findings in Pick’s disease. In: Zimmerman HM (eds) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 421–452
  9. Brown DR (2001) Copper and prion disease. Br Res Bull 55:165–173 · DOI · Paper page
  10. Brunk UT, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mut Res 275:395–403 · DOI · Paper page
  11. Bush AI, Huang X, Fairlie DP (1999) The possible origin of free radicals from amyloid β-peptides in Alzheimer’s disease. Neurobiol Ageing 20:335–337 · DOI
  12. Butterfield DA, Kanski J (2001). Brain oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945–962 · DOI · Paper page
  13. Cherny RA, Barnham KJ, Lynch T et al (2000). Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer’s disease. J Struct Biol 130:209–216 · DOI
  14. Chetley A, Gilbert D (1986) Health action international. International Organisation of Consumers Unions, The Hangue
  15. Claesen ME, Clements ML (1989) Ridding the world of hydroxyquinolines. Br Med J 299:527–528 · DOI
  16. Cohen AS, Shirahama T, Skinner M (1982) Electron microscopy of amyloid. In: Harris JR (eds) Electron microscopy of proteins, vol 3. Academic Press, London UK, pp 165–205
  17. Cohen FE (1999) Protein misfolding and prion diseases. J Mol Biol 293:313–320 · DOI
  18. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291–20299 · DOI · Paper page
  19. Crapper Mclachlan DR, Dalton AJ, Kruck TPA et al (1991) Effect of desferrioxamine on the clinical progress of Alzheimer’s disease. Lancet 337:1304–1308 · DOI · Paper page
  20. Crossthwaite AJ, Williams RJ (2002) Hydrogen peroxide-mediated phosphorilation of ERK1/2, Akt/PKB and JNK in cortical neurons: dependence on Ca2+ and PI 3-kinase. J Neurochem 80:24–36 · DOI · Paper page
  21. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285–298 · DOI · Paper page
  22. Di Patti MC, Persichini T, Mazzone V, Polticelli F, Colasanti M, Musci G (2004) Interleukin-1 beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci Lett 363:182–186 · DOI
  23. Dobson MC (2003a) Protein folding and disease: a view from the first horizon symposium. Nat Drug Disc 2:154–160 · DOI
  24. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and Locus caeruleus in Parkinson’s disease. J Neuropathol Exp Neurol 24:398–414 · DOI · Paper page
  25. Floyd RA (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236–245 · DOI · Paper page
  26. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23:795–807 · DOI · Paper page
  27. Gotz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: Free radical production in neural degeneration. Pharmacol Ther 63:37–122 · DOI · Paper page
  28. Grunblatt E, Mandel S, Youdim MB (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies. J Neurol 247(Suppl 2):95–102 · DOI
  29. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC (1999) Investigation into the correlation between the structure of hydroxypyridinones and blood–brain barrier permeability. Biochem Pharmacol 57:1305–1310 · DOI
  30. Harris DC, Aisen P (1973) Facilitation of Fe(II) autoxidation by Fe(III) complexing agents. Biochim Biophys Acta 329:156–158 · DOI · Paper page
  31. Hartley DM, Walsh DM, Ye CP et al (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurones. J Neurosci 19(20):8876–8884 · DOI · Paper page
  32. Hedge ML, Jagannatha Rao KS (2003) Challenges and complexities of α-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys 418:169–178 · DOI
  33. Hider RC, Hall AD (1991) Clinically useful chelators of tripositive elements. Prog Med Chem 28:41–173 · DOI
  34. Hider RC (1995) Potential protection from toxicity by oral iron chelators. Toxicol Lett 82–83:961–967 · DOI
  35. Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R (2003) Copper binding to PrPC may inhibit prion disease propagation. Br Res 993:192–200 · DOI
  36. Hirsh EC, Brandel J-P, Galle P (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56:446–451 · DOI · Paper page
  37. Holander D, Ricketts D, Boyd CAR (1988) Importance of probe molecular geometry in determining intestinal permeability. Can J Gastroenterol 2:35A–38A
  38. Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102 · DOI · Paper page
  39. Huang X, Atwood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616 · DOI · Paper page
  40. Jeffrey M, Goodsir CM, Bruce ME, Mcbride PA, Scott JR (1994) Infection-specific prion protein (PrP) accumulates on neuronal plasmalemma in scrapie-infected mice. Ann NY Acad Sci 724:327–330 · DOI
  41. Jelliger KA (1999) The role of iron in neurodegeneration: prospects for pharmacology of Parkinson’s disease. Drugs Aging 14:115–140 · DOI · Paper page
  42. Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37:899–909 · DOI · Paper page
  43. Laine J, Marc M-E, Sy M-S, Axelrad H (2001) Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. Eur J Neurosci 14:47–56 · DOI
  44. Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104:469–481 · DOI · Paper page
  45. Lee J-Y, Friedman JE, Angel I, Kozak A, Kohj JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol aging 25:1315–1321 · DOI · Paper page
  46. Levine SM, Chakrabarty A (2004) The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1012:252–266 · DOI · Paper page
  47. Liu ZD, Lockwood M, Rose S, Theobald AE, Hider RC (2001) Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem Pharmacol 61:285–290 · DOI
  48. Liu ZD, Hider RC (2002a) Design of clinically useful iron(III)-selective chelators. Med Res Rev 22:26–64 · DOI · Paper page
  49. Liu ZD, Kayyali R, Hider RC, Porter JB, Theobald AE (2002) Design, synthesis, and evaluation of novel 2-substitued 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J Med Chem 45:631–639 · DOI
  50. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T (2006) Long-lasting neural and behavioural effects of iron deficiency in infancy. Nutr Rev 64:S34–43 · DOI · Paper page
  51. Lue LF, Kuo Y-M, Roher AE et al (1999) Soluble amyloid β-peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862 · DOI · Paper page
  52. Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res Mol Brain 134(1):18–23 · DOI
  53. Mandel S, Weinreb O, Amit T, Youdim MB (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48:379–387 · DOI · Paper page
  54. Martell AE, Smith RM (1974–1989) Critical stability constant, vol 1–6. Plenum Press, London
  55. Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS (1986). Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 71:71–80 · DOI · Paper page
  56. Mc Lean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866 · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
  57. Merz PA, Sommerville RA, Wisniewsky HM, Ikbal K (1981). Abnormal fibrils from scrapie-infected brain. Acta Neuropathol 54:63–74 (Berlin) · DOI · Paper page
  58. Mizuno Y, Ohta S, Tanaka M et al (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455 · DOI · Paper page
  59. Molina-Holgado F, Williams RJ, Gaeta A et al (2006) Neuroprotective actions of an iron chelator against Alzheimer’s disease-relevant insults. Poster session, 10th international conference on Alzheimer’s disease and related disorders’s, Madrid, Spain
  60. Oakley GP (1973) The neurotoxicity of the halogenated hydroxyquinolines. JAMA 225(4):395–397 · doi:10.1001/jama.1973.03220310031006
  61. O’Brien-Ladner AR, Nelson SR, Murphy WJ, Blumer BM, Wesselius LJ (2000) Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung. Am J Respir Cell Mol Biol 23:112–119 · DOI
  62. Olanow CW (1992) Magnetic resonance imaging in parkinsonism. Neurol Clin North Am 405–420 · DOI
  63. Olanow CW, Youdim MB (1996) Neurodegeneration and neuroprotection in Parkinson’s disease. Academic Press, pp 55–59 · DOI
  64. Olivieri N, Koren G, Hermann C et al (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275–1279 · DOI · Paper page
  65. Paik SR, Shin H-J, Lee J-H, Chang C-S, Kim J (1999) Copper(II)-induced self-oligomerisation of α-synuclein. Biochem J 340:821–828 · doi:10.1042/bj3400821 · Paper page
  66. Palm A (1932) Untersuchung in des chinolin reihe. Arch Exp Pathol Pharmacol 199:176–185 · DOI
  67. Pan K, Baldwin M, Nguyen J et al (1993) Conversion of α-helices β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962–10966 · DOI · Paper page
  68. Prusiner SB, Mckinley MP, Bowman KA et al (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349–358 · DOI · Paper page
  69. Prusiner SB (1991) Molecular biology of prion disease. Science 252:1515–1522 · DOI · Paper page
  70. Prusiner SB (2001) Neurodegenerative diseases and prions. N Engl J Med 344:1516–1526 · DOI · Paper page
  71. Riederer P, Sofic E, Rausch WD, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515–520 · DOI · Paper page
  72. Rochet JC, Lansbury PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60–80 · DOI · Paper page
  73. Roher AE, Chaney MO, Kuo Y-M et al (1996) Morphology and toxicity of Aβ-(1–12) dimmer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271:20631–20635 · DOI · Paper page
  74. Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 5:535–551 · DOI
  75. Rose FC, Gawel M (1984) Clioquinol neurotoxicity: an overview. Acta Neurol Scand 80(Suppl 100):137–145
  76. Saggu H, Cooksey J, Dexter D (1989) A selective increase in a particular superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 53:692–697 · DOI · Paper page
  77. Sanchez-Ramos J, Overvick E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2’-deoxy-guanoxine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3:197–204
  78. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross β-conformation. Proc Natl Acad Sci USA 97:4897–4902 · DOI · Paper page
  79. Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1–7 · DOI · Paper page
  80. Sherki YG, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:959–975 · DOI · Paper page
  81. Shin R-W, Kruck TPA, Murayama H, Kitamoto T (2003) A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease. Br Res 961:139–146 · DOI
  82. Sikorski P, Atkins EDT, Serpell LC (2003) Structure and texture of fibrous crystals formed by Alzheimer’s Aβ (11–15) peptide fragment. Structure 11:915–926 · DOI
  83. Sofic E, Riederer P, Heinsen H (1988) Increased Iron(Iii) and total iron content in post mortem, substantia nigra of parkinsonian brain. J Neural Trans 74:199–205 · DOI · Paper page
  84. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130 · DOI · Paper page
  85. Stahl N, Borchelt DR, Hsiao K, Prusiner SB (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51:229–240 · DOI · Paper page
  86. Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580 · DOI · Paper page
  87. Torok M, Milton S, Kayed R et al (2002) Structural and dynamic features of Alzheimer’s Aβ peptide in amyloid fibrils studied by site-directed spin labelling. J Biol Chem 277:40810–40815 · DOI · Paper page
  88. Tsubaki T, Honma Y, Hosh M (1971) Neurological syndrome associated with clioquinol. Lancet 1:696–697 · DOI
  89. Tycko R (2004) Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol 14:1–8 · DOI · Paper page
  90. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB (1993) Characterisation of amyloid peptide from human cerebrospinal fluid. J Neurochem 61:1965–1968 · DOI · Paper page
  91. Wang SS, Becerra-Arteaga A, Good TA (2002) Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol Bioeng 80:50–59 · DOI
  92. Wisniewsky HM, Coblentz JM, Terry RD (1972) Pick’s disease. A clinical and ultrastructural study. Arch Neurol 26:97–108 · DOI
  93. Xu J, Kao S-Y, Lee FJS, Song W, Jin L-W, Yankner BA (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606 · DOI · Paper page
  94. Ye FQ, Allen PS, Martin WRW (1996) Basal ganglia iron content in Parkinson’s disease measured with magnetic resonance. Mov Disord 11:243–249 · DOI
  95. Yokel RA, Fredenburg AM, Meurer KA, Skinner TL (1995) Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab Dispos 23:1178–1180
  96. Youdim MB, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson’s disease with iron chelators. Ann NY Acad Sci 890:7–25 · DOI
  97. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510:216–220 · DOI · Paper page
  98. Zhang X, Haaf M, Todorich B et al (2005) Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 52(3):199–208 · DOI

Cited by

See all 207

Metadata

Authors
Molina-Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P.
Venue
BioMetals
Published
2007-02-09
Volume
20
Issue
3-4
Pages
639-654
ISSN
  • 0966-0844 (ISSN-L)
  • 1572-8773
OpenAlex
W2068609215
Cited by
207
References
26
FWCI
12.06
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metals ions and neurodegeneration. https://app.cochat.ai/papers/10.1007/s10534-006-9033-z
The paper
Molina-Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P. (2007). Metals ions and neurodegeneration. BioMetals. https://doi.org/10.1007/s10534-006-9033-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.